Which manufacturer is Delamanid?

Delamanid (Delamanid) is an innovative anti-tuberculosis drug specially used to treat multi-drug-resistant tuberculosis (MDR-TB). It belongs to the nitroimidazole class of compounds. Its main mechanism of action is to inhibit the cell wall synthesis of Mycobacterium tuberculosis, thereby blocking bacterial proliferation and spread. This unique targeting mechanism makes it of great value in the treatment of drug-resistant tuberculosis. The clinical application of delamanid is especially targeted at adult patients who are resistant or intolerant to conventional anti-tuberculosis drugs, providing a new treatment method for the global anti-tuberculosis strategy.

The original drug of delamanid is developed and produced by a Japanese pharmaceutical company**Otsuka Pharmaceutical Co., Ltd.**. Otsuka has extensive experience in global anti-tuberculosis drug research and development, and its research and development team has verified through years of clinical trials to ensure that delamanid is both safe and effective in MDR-TB patients. The company not only invests a lot of resources in drug research and development, but also establishes a complete drug registration, supply chain and global distribution system to ensure that patients can obtain a stable supply of drugs.

Up to now, only the original version of Delamani has been sold in the domestic market, and no generic drugs have yet appeared. Strict quality control of original drugs ensures the consistency of the drug's ingredient stability, absorption rate and efficacy, which is also the first choice for clinical use. Since the treatment of multi-drug-resistant tuberculosis requires a combination of multiple drugs, Otsuka's original drug shows good safety and controllability in the combination regimen, while providing patients with clear medication guidance and monitoring plans.

Delamani's production and quality management strictly follow international pharmaceutical production standards, and its drug stability and bioavailability have been clinically verified to ensure that patients receive safe and reliable treatment. For global tuberculosis prevention and control, Dramani not only provides new treatment options, but also provides scientific basis for public health policy formulation.

Reference: https://go.drugbank.com/drugs/DB11637